The aim of the present work was to use GastroPlus™ software for the prediction of pharmacokinetic profiles and in vitro-in vivo correlation (IVIVC) as tools to optimize the development of new generic medications.
Physiologically Based Pharmacokinetic Modelling to Predict Single- and Multiple-Dose Human Pharmacokinetics of Bitopertin
This paper describes the use of physiologically based pharmacokinetic (PBPK) modelling and preclinical data to gain insights into and predict bitopertin clinical pharmacokinetics.
In Vitro Characterization of Axitinib Interactions with Human Efflux and Hepatic Uptake Transporters: Implications for Disposition and Drug Interactions
Axitinib is an inhibitor of tyrosine kinase vascular endothelin growth factor receptors 1, 2, and 3. The ATP-binding cassette (ABC) and solute carrier (SLC) transport properties of axitinib...
Investigation of clinical pharmacokinetic variability of an opioid antagonist through physiologically based absorption modeling
Identifying the source of inter- and/or intrasubject variability in pharmacokinetics (PK) provides fundamental information in understanding the pharmacokinetics-pharmacodynamics relationship...
Simulations Plus Completes Molecule Design Phase of Second NCE Project, Issues RFQs for Molecule Synthesis
Company Uses Proprietary Software Tools to Design New Molecules for COX-2 Inhibitors
Simulations Plus Completes Collaboration with Bayer HealthCare to Enhance Important Property Prediction in ADMET Predictor™
Prediction of Ionization Constants Key to Many Other Property Predictions
Simulations Plus Announces Quarterly Cash Dividend Increase
Board increases cash dividend again to $0.03 per share
Simulations Plus Releases MedChem Studio™ 3.5 and MedChem Designer™ 2.5
Software Upgrades Further Expand Powerful Data Mining and Molecule Design Programs, Extend Technological Lead of Simulations Plus
Simulations Plus Reports Third Quarter and First Nine Months FY2013 Financial Results
Third quarter net sales increase 11.7%; net income up 14.3%
Simulations Plus Sets Date for 3rd Quarter 2013 Earnings Release and Conference Call
Conference Call to be on Thursday, July 11, at 4:15 PM ET
Dendritic Cell Immunoreceptor Is a New Target for Anti-AIDS Drug Development: Identification of DCIR/HIV-1 Inhibitors
The HIV-1 pandemic continues to expand while no effective vaccine or cure is yet available. Existing therapies have managed to limit mortality and control viral proliferation, but are associated with side effects...
Similarity-based virtual screening for microtubule stabilizers reveals novel antimitotic scaffold
Microtubules are among the most studied and best characterized cancer targets identified to date. Many microtubule stabilizers have been introduced so far that work by disrupting the...
Low systemic testosterone levels induce androgen maintenance in benign rat prostate tissue
Prostate cancer (PC) is both an age- and an androgen-dependent disease. Paradoxically, systemic levels of androgens decline with age as the risk of PC rises. While there is no...
Physicochemical and biopharmaceutical properties
This webinar describes our modeling methodology and highlights the performance of key models. Special attention is devoted to our novel method of predicting macroscopic pKa, and our "Absorption Risk" Score.
It’s like playing with a better tennis partner
Are you a whistle-blower? Or do you cringe just to read those words? According to Margaret Heffernan* (links to a dead link) in a 2012 TEDTalk, most whistle-blowers are good guys. A whistle-blower can provide constructive conflict, which is vital for success. Heffernan says that great research teams, relationships, and businesses allow people to deeply disagree. When we are afraid of conflict, our doubts remain hidden. But when we dare to break that silence – when we dare to create conflict – we enable ourselves and the people around us to do our very best thinking.
Physiologically based pharmacokinetic and pharmacodynamic modeling of an antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer
The inhibitors of apoptosis proteins (IAPs) are a class of key apoptosis regulators overexpressed or dysregulated in cancer. SM-406/AT-406 is a potent and selective small molecule mimetic of...
Simulations Plus Signs Material Transfer Agreement with National Institute of Environmental Health Sciences
Software Programs Will Help Prioritize Testing for the National Toxicology Program
A population pharmacokinetic and pharmacodynamic analysis of peginesatide in patients with chronic kidney disease on dialysis
Peginesatide (OMONTYS®) is an erythropoiesis-stimulating agent that was indicated in the United States for the treatment of anemia due to chronic kidney disease in adult patients on dialysis prior to...
Intelligent Wondering 8211 Investigative Clinical Pharmacology
Reviews of new drug applications by regulatory authorities worldwide grow ever more rigorous. I think that one reason for this heightened scrutiny is that reviewers have, over the last 10 years, read many submissions containing results of pharmacometric modeling and simulation analyses. With the use of modeling, explorations of the determinants of drug efficacy and safety are more thorough, and the analyses provide solid support for dose recommendations and labeling content. In short, I think that model-based analyses have raised reviewers’ expectations.
Simulations Plus Reports Preliminary Revenues for Third Fiscal Quarter FY2013
Preliminary Revenues Increased 11.7% for New Record Third Quarter